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S U M M A R Y
Objectives: A chikungunya epidemic occurred in 2013–2014 in the Caribbean and Americas. Although
the disease is usually benign, some patients required admission to the intensive care unit (ICU). The
characteristics and outcomes of patients with chikungunya virus (CHIKV) infection admitted to an ICU
during this epidemic are reported.
Methods: An observational study of consecutive patients with conﬁrmed CHIKV infection admitted to
ICUs in Martinique and Guadeloupe, French West Indies, between January and November 2014, was
performed. In addition, patients with CHIKV-related manifestations were compared with those whose
manifestations were not speciﬁcally related to CHIKV infection.
Results: Sixty-ﬁve patients were admitted to the ICU with CHIKV infection. Fifty-four (83%) had a pre-
existing underlying disease and 27 (41.5%) were admitted due to exacerbation of a comorbidity. Thirty-
seven (57%) patients were mechanically ventilated. ICU and hospital mortality rates were 26% and 27%,
respectively. CHIKV-related manifestations were observed in 28 (18%) patients and were mainly
encephalitis, Guillain–Barre´ syndrome, and severe sepsis. These patients less frequently had chronic
arterial hypertension and diabetes and more frequently had autoimmune diseases compared with
patients without CHIKV-related manifestations.
Conclusions: Most patients admitted to the ICU with CHIKV infection had a pre-existing comorbidity.
However, severe manifestations such as Guillain–Barre´ syndrome, encephalitis, and severe sepsis could
be speciﬁcally related to CHIKV.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Chikungunya fever (CHIKF) is an arboviral disease that was ﬁrst
identiﬁed in 1953.1 The causal agent, chikungunya virus (CHIKV), is
transmitted to humans by mosquitoes of the Aedes genus.1
Epidemics of CHIKF have occurred mainly in Africa and Southeast
Asia. In October 2013, CHIKV was detected in Saint Martin and
thereafter spread rapidly throughout the Caribbean and the* Corresponding author at: Intensive Care Unit, University Hospital of Pointe a`
Pitre, 28 route chauvel, Les Abymes, Guadeloupe 97139, France.
E-mail address: guillaume.thiery@chu-guadeloupe.fr (G. Thie´ry).
1 These authors contributed equally to this article.
http://dx.doi.org/10.1016/j.ijid.2016.05.010
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Americas,2 affecting more than a million patients in 42 territories.3
In the French West Indies, 159 623 suspected cases have been
reported, representing more than 17% of the total population.2,3
Although CHIKF is usually benign, severe forms of the disease have
been described,4 and the need for admission to the intensive care
unit (ICU) was reported for the ﬁrst time during the epidemics in
Reunion Island in 2006.5,6
2. Methods
This study aimed to describe the critically ill patients with
CHIKV infection admitted to ICUs of the university hospitals in
Guadeloupe and Martinique during the 2013–2014 Caribbeanociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Clinical and laboratory features and outcomes of 65 patients with chikungunya
virus infection admitted to the ICU
Characteristic N = 65
Age, years, median (IQR) 63 (52–70)
Sex, male, n (%) 41 (63)
Pre-existing disease, n (%)
Hypertension 36 (55)
Diabetes mellitus 21 (32)
Chronic renal failure 13 (20)
Chronic heart failure 13 (20)
Autoimmune disease 5 (8)
Including lupus 3 (5)
Sickle cell disease 4 (6)
No pre-existing disease 11 (17)
Diagnosis of chikungunya, n (%)
PCR 38 (58)
IgM 34 (52)
Both PCR and IgM 7 (11)
Laboratory ﬁndings on admission
WBC count,  109/l, median (IQR)a 10.2 (6.7–14.0)
Lymphocyte count,  109/l, median (IQR) 0.86 (0.45–1.25)
Lymphopenia <1  109/l, n (%) 42 (65)
Platelet count,  109/l, median (IQR) 150 (101–220)
Platelet count <150  109/l, n (%) 33 (51)
Creatinine level, mmol/l, median (IQR) 142 (85–371)
CK level, mmol/l, median (IQR)b 699 (344–3799)
CK level >1000 mmol/l, n (%) 21 (32.3)
ALT levels, IU/l, median (IQR)c 37 (22–108)
CRP levels, mmol/l, median (IQR) 66 (27–235)
Lactate level, mmol/l, median (IQR)c 2.2 (1.4–5.2)
Organ failure on admissiond, n (%)
Haemodynamic 29 (45)
Renal 27 (41)
Neurological 18 (28)
Respiratory 17 (26)
Hepatic 17 (26)
Haematological 13 (20)
ICU management-associated variables
SAPS II, median (IQR) 39 (28–54)
Vasopressor supporte, n (%) 30 (46)
Mechanical ventilatione, n (%) 37 (57)
Renal replacement therapyf, n (%) 20 (31)
Outcome variables
ICU length of stay, days, median (IQR) 6 (4–11)
Hospital length of stay, days, median (IQR) 16 (8–24)
Crude ICU mortality, n (%) 17 (26)
Crude hospital mortality, n (%) 18 (27)
ICU, intensive care unit; IQR, interquartile range; PCR, polymerase chain reaction;
WBC, white blood cell; CK, creatinine kinase; ALT, alanine aminotransferase; CRP, C-
reactive protein; SAPS, Simpliﬁed Acute Physiology Score; SOFA, Sequential Organ
Failure Assessment.
a Data missing for two patients.
b Data missing for 13 patients.
c Data missing for ﬁve patients.
d Organ failure was deﬁned as a SOFA score of 3 for each organ.
e During the ﬁrst 48 h.
f At any time during the ICU stay.
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French West Indies. From January to November 2014, at the height
of the outbreak, clinical and laboratory data were collected from
each consecutive patient with CHIKV infection conﬁrmed by either
a positive real-time PCR (RT-PCR) or positive IgM serology. RT-PCR
(RealStar Chikungunya RT-PCR Kit 1.0; Altona Diagnostics) was
performed on the serum and cerebrospinal ﬂuid (CSF), when
available, between days 1 and 10 of symptoms. IgM testing was
performed from day 5 after the ﬁrst symptoms. Organ failure was
assessed during the ﬁrst 48 h after admission and was deﬁned as a
Sequential Organ Failure Assessment (SOFA) score of 3 or
4. Encephalitis was deﬁned based on the diagnostic criteria of
the Consensus Statement of the International Encephalitis
Consortium.7 Severe sepsis and septic shock were deﬁned
according to the International Sepsis Deﬁnitions Conference.8
Patients with CHIKV-related manifestations were deﬁned as those
lacking any other acute cause or predisposing medical condition
identiﬁed to explain the acute illness; these patients were
compared to patients whose manifestations were not directly
related to CHIKV infection.
3. Results
During the study period CHIKF was conﬁrmed in 65 patients.
Baseline characteristics for CHIKF patients are shown in
Table 1. Fifty-four patients (83%) had a pre-existing disease,
predominantly chronic hypertension, diabetes mellitus, chronic
heart failure, and chronic renal failure. Thirty-seven (57%) patients
required invasive mechanical ventilation, 30 (46%) had shock and
needed vasoactive drugs, and 20 (31%) required renal replacement
therapy. ICU and hospital crude mortality rates were 26% and 27%,
respectively, and were similar to the global mortality rate in each
ICU.
CHIKV-related manifestations, such as a central or peripheral
neurological disorder and severe sepsis or septic shock, were
observed in 18 (28%) patients. Five patients (8%) demonstrated
disorders of the central nervous system (CNS), including three who
met criteria for encephalitis and two who had diffuse brain
ischemia leading to brain death. In addition, six patients (9%) had
Guillain–Barre´ syndrome. Six patients (9%) had severe sepsis
(n = 3) and septic shock (n = 3) that was neither clinically nor
microbiologically documented and for whom the only infectious
agent identiﬁed was CHIKV. CHIKV-related myocarditis was
diagnosed in one patient.
Patients with CHIKV-speciﬁc manifestation and those without
did not differ in terms of organ failure, Simpliﬁed Acute Physiology
Score (SAPS II), or laboratory ﬁndings, as reported in Table 2. More
patients with CHIKV-related manifestations had autoimmune
diseases. In addition, they less frequently required renal replace-
ment therapy and had a shorter length of stay in the ICU. There was
no difference in crude mortality rate between the two groups.
4. Discussion
This study reports a large cohort of patients with CHIKV
infection admitted to the ICU. As reported previously during the
Reunion Island epidemic, severe manifestations affect only a small
number of patients in the total infected population,6 and are
predominantly seen in patients with debilitating conditions, in
whom CHIKV infection often triggers an exacerbation of a pre-
existing disease.
It is well documented that CHIKV infection can affect the
nervous system.9 In this study, 10 out of 65 (17%) patients
presented with an acute neurological disease possibly related to
CHIKV infection. Encephalopathy has so far appeared to represent
the most common neurological manifestation; this was reported in19 out of 33 patients hospitalized in the ICU during the Reunion
Island epidemics.6 However, only three patients in the present
series had criteria for encephalitis. This difference may be
explained by the strict criteria for encephalitis used in the present
study.7 The high incidence of Guillain–Barre´ syndrome is consis-
tent with reports from previous epidemics.6,10 It is also consistent
with the probable link between Guillain–Barre´ syndrome and
other arboviral diseases, such as Zika virus infection and dengue
fever.
CHIKV-related severe sepsis or septic shock was present in six
patients. This complication has not been observed in previous
outbreaks, but has been reported since the beginning of the current
epidemic in some patients in Colombia and Venezuela, including
some cases of multiple organ failure with fatal outcome.11,12
Hemodynamic failure is also observed in other arboviral diseases,
Table 2
Comparison of characteristics and outcomes of patients with chikungunya virus-related manifestations and patients without chikungunya virus-related manifestations
Patients with CHIKV-related manifestationsa
n (%) (n = 18)
Patients without CHIKV-related manifestations
n (%) (n = 47)
p-Valueb
Sex, male 13 (72) 28 (60) 0.89
Age, years, median (IQR) 60 (52–65) 65 (48–72) 0.97
Pre-existing disease
Hypertension 4 (22) 32 (68) 0.002
Diabetes mellitus 1 (5) 20 (43) 0.01
Chronic renal failure 2 (11) 11 (23) 0.45
Chronic heart failure 1 (5) 12 (26) 0.15
Autoimmune disease 4 (22) 1 (2) 0.03
Organ failure on admission
Haemodynamic 6 (33) 22 (47) 0.33
Renal 4 (22) 23 (49) 0.09
Neurological 6 (33) 12 (25) 0.53
Respiratory 3 (17) 13 (28) 0.56
Hepatic 4 (22) 13 (28) 0.9
Haematological 5 (28) 8 (17) 0.53
ICU management-associated variables
SAPS II, median (IQR) 38 (25–52) 40 (29–54) 0.34
Vasopressor support 7 (39) 22 (47) 0.56
Mechanical ventilation 12 (66) 25 (53) 0.33
Renal replacement therapy 1 (6) 19 (40) 0.01
Laboratory ﬁndings on admission
Lymphocyte count,  109/l, median (IQR)c 0.85 (0.38–1.2) 0.86 (0.54–1.41) 0.49
Lymphopenia <1  109/l 13 (72) 28 (68) 0.53
Platelet count,  109/l, median (IQR) 143 (84–240) 153 (104–219) 0.52
Platelet count <150  109/l 9 (50) 23 (49) 0.94
Lactate level, mmol/l, median (IQR)d 2.6 (1.9–3.7) 2 (1.2–5.4) 0.45
Lactate level >4 mmol/l 6 (33) 20 (43) 0.5
LOS ICU, days, median (IQR) 8 (5–20) 6 (3–11) 0.05
Crude ICU mortality 4 (22) 13 (28) 0.76
CHIKV, chikungunya virus; IQR, interquartile range; ICU, intensive care unit; SAPS, Simpliﬁed Acute Physiology Score; LOS, length of stay.
a Patients with CHIKV-speciﬁc manifestations had encephalitis (n = 3), brain ischemia (n = 2), Guillain–Barre´ syndrome (n = 6), severe sepsis or septic shock (n = 6), and
myocarditis (n = 1).
b Categorical variables were compared using the Khi 2 test or Fisher’s exact test, as appropriate, and continuous variables were compared using the non-parametric Mann–
Whitney test. p-Values of less than 0.05 were considered statistically signiﬁcant.
c Data missing for two patients.
d Data missing for ﬁve patients.
L. Crosby et al. / International Journal of Infectious Diseases 48 (2016) 78–8080such as dengue fever. Although the pathophysiology is unclear, a
cytokine storm induced by the virus similar to that observed in
sepsis has been suggested.
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